Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of NNC0487-0111 in Hepatic Impairment
NCT07587710Phase 1Not yet recruiting
- Sponsor
- Novo Nordisk
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of amycretin in obesity and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the plasma concentration-time curve from time 0 to infinity. Planned start May 2026; status: not yet recruiting.
02
Drugs
amycretin
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07587710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07587710.